Company Overview and News

1
Avinger's (AVGR) CEO Jeff Soinski on Q2 2018 Results - Earnings Call Transcript

2018-08-14 seekingalpha
Greetings. And welcome to the Avinger’s Second Quarter 2018 Earnings Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]
AVGR

1
AVGR / Avinger, Inc. 10-Q (Quarterly Report)

2018-08-13 sec.gov
Table of Contents
AVGR

1
AVGR / Avinger, Inc. 8-K (Current Report)

2018-08-08 sec.gov
UNITED STATES<
AVGR

1
AVGR / Avinger, Inc. / ARMISTICE CAPITAL, LLC - null (Passive Investment)

2018-07-23 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
AVGR

1
AVGR / Avinger, Inc. / ARMISTICE CAPITAL, LLC - null (Passive Investment)

2018-07-23 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
AVGR

1
AVGR / Avinger, Inc. 424B5 (Prospectus)

2018-07-13 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement Table of Contents
AVGR

1
AVGR / Avinger, Inc. 8-K (Current Report)

2018-07-13 sec.gov
UNITED STATES<
AVGR

3
Avinger Announces Pricing of $3.55 Million Registered Direct Offering

2018-07-12 globenewswire - 2
REDWOOD CITY, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,166,180 shares of common stock at a price of $1.6425 per share in a registered direct offering, resulting in total gross proceeds of approximately $3.
LTS-A AVGR LTS

81
Avinger Appoints Mark Weinswig as Chief Financial Officer

2018-06-13 globenewswire - 2
REDWOOD CITY, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial Officer (CFO) effective June 25, 2018. Mr. Weinswig will succeed Matt Ferguson, who will be leaving the Company to pursue other opportunities.
AVGR MS AQMS

65
AVGR / Avinger, Inc. 8-K (Current Report)

2018-06-13 sec.gov - 3
UNITED STATES<
AVGR

75
AVGR / Avinger, Inc. 8-K (Current Report)

2018-06-11 sec.gov - 13
UNITED STATES
AVGR

80
AVGR / Avinger, Inc. 8-K (Current Report)

2018-06-05 sec.gov - 18
UNITED STATES
AVGR

76
Rounds Report: Crispr Rallied While The FDA Approved Lumivascular

2018-05-25 seekingalpha - 1
The bioscience market logged further gains for the second consecutive day this week. Many equities under our coverage continued to move northbound.
AVGR CRSP IBB K XBI

78
AVGR / Avinger, Inc. 10-Q (Quarterly Report)

2018-05-15 sec.gov - 16
Table of Contents
AVGR

78
AVGR / Avinger, Inc. 8-K/A (Current Report)

2018-05-15 sec.gov - 16
UNITED STATES
AVGR

AVGR : Avinger Stock Analysis and Research Report

2017-11-10 - Asif

Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease, or PAD. Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system available in this market. The company manufacture and sell a suite of products in the United States and select international markets. The company's current products include its Lightbox imaging console, as well as its Wildcat, Kittycat 2, and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion, or CTO, and Pantheris, its image-guided atherectomy ...

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 053734109